Stephen Liu, Chief, Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared on LinkedIn:
“Looking forward to an eventful ESMO26!
On Sunday, 25 October, at 1pm CEST in Madrid, join Drs. Antonio Passaro, Antonio Calles, Lizza Hendriks and me in IFEMA Hall 4 as we discuss the rapidly evolving treatment landscape for EGFR mutant NSCLC. Hope to see you there!”
To which David Planchard, Medical Oncologist at University Paris Saclay, added:
” Thrilled to see the new treatment options post Osi-ChemoT 1L with the SAFFRON results, BsAbs (PD1/VEGF, EGFR/MET), bispecific-ADCs (EGFR/HER3), and ADCs (TROP2).
Incredible lineup of options post-Osi/ChemoT!”
This also can be interesting:
